Abemaciclib in the Adjuvant Setting for Breast Cancer: A Systematic Review

The combination of adjuvant Abemaciclib with endocrine therapy (ET) has emerged as a significant advancement in the management of HR+, HER2-, node-positive, high-risk early breast cancer, as demonstrated by the findings of the MonarchE trial. This innovative treatment approach yielded not only statistically significant but also clinically meaningful improvements in invasive disease-free survival.

Moreover, the benefits of this treatment combination were sustained over time, with a median follow-up of 27 months revealing continued clinically meaningful advantages in both invasive disease-free survival and distant recurrence-free survival. Importantly, these benefits extended beyond the initial 2-year treatment period, highlighting the durable efficacy of Abemaciclib and ET in preventing disease progression and distant metastasis.

Furthermore, the safety profile of the combination therapy was found to be manageable and tolerable. This aspect is crucial for ensuring patient adherence to treatment and minimizing the burden of adverse effects. Overall, these findings underscore the potential of adjuvant Abemaciclib with ET as a valuable therapeutic option for patients with high-risk early breast cancer, offering both efficacy and tolerability in the long-term management of the disease. More studies are required, especially in the elderly, in order to know how to counteract diarrhea and to make Abemaciclib more tolerated.